In a study, Australian ophthalmology and optometry researcher and Beatles fan Professor Stephen Vincent has analyzed John Lennon’s little-known, hit-and-miss use of contact lenses in the 1960s and found the Rock and Roll Hall of Famer was probably right when he theorized that his cannabis use helped them stay in place.
EC-104 is a novel intravitreal (IVT) corticosteroid implant with intended 6 months durable drug release for the treatment of DME.
The growing body of evidence that suggests that maintaining adequate levels of vitamin D may be beneficial for preventing and managing RVO.
This Week in Ophthalmology is a video series highlighting some of the top articles featured on the Ophthalmology Times website.
Stephen R. Russell, MD, discussed the 9-year data he presented at the American Society of Retina Specialists annual meeting for voretigene neparvovec-rzyl.
In English and Spanish TV and radio spots, the public is urged to protect their vision from preventable blindness and vision loss by seeking care from a retina specialist at the first sign of retinal disease.
Eastern Kentucky University student Madison Carlisle experienced rapid vision loss until the team at UK HealthCare was able to unravel the source of her issues.
Sadda is the second person to serve as chair. The first chairholder was John Irvine, MD, who was appointed to the role in 2001.
EC-104 is a novel intravitreal (IVT) corticosteroid implant with intended 6 months durable drug release for the treatment of DME.
Technologies continue to push retina surgical suites into the future
The NIH-funded study finds lack of coverage, copays, restrictive policies barriers to vital eye care for adults.
According to the company, the priority review voucher would be issued upon approval of ATSN-201, a gene therapy product candidate.
The LIGHTHOUSE study a Phase I/II, open-label, dose-escalation and dose-expansion clinical trial is currently investigating the safety and tolerability of ASTN-201 for XLRS.
US District Court Judge Anne Nardacci, presiding in the Northern District of New York, ruled David Kwiat, MD, and Kwiat Eye and Laser Surgery PLLC illegally retaliated against the employee based on protected activity.
Physicians share comprehensive approaches during roundtable discussion.
Smaller surgeries, in greater numbers, await new glaucoma specialists
The Australian Society of Ophthalmologists hosted its inaugural Eye Surgery Showcase, where participants learned how ophthalmologists and the medical technology industry are working together to save the sight of Australians.
A team of researchers from Portugal and Belgium presented a paper highlighting the case of a patient with conjunctival CAM and offered an overview of the differential diagnosis and management of pigmented lesions of the conjunctiva.
Tim Cherry, PhD, and Debarshi Mustafi, MD, PhD, have been awarded a $150,000 Clinical & Research Synergy Pilot Award from Seattle Children’s Research Institute to determine the genetic causes of unsolved inherited retinal diseases.
Researchers noted that patients with sickle cell disease had an increased risk of developing any retinal vascular occlusion.
Current Fuchs endothelial corneal dystrophy treatments include implanted cultured human endothelial cells.
Determining the medication’s safety and efficacy for paediatric patients
The authors explained that estimating the number of such visits in the US may help guide research and clinical efforts to optimize outcomes.
Lupin has successfully completed a clinical study of LUBT010, a ranibizumab biosimilar to Lucentis
The FDA has a 60-day filing review period to determine whether the NDA submission is complete and acceptable for review.
The biosimilar is indicated to improve and maintain visual acuity for patients with neovascular age-related macular degeneration
According to the company, the FDA approval strengthens its biosimilar position in the US market.
